The muscarinic cholinergic receptor (mAChR) antagonist scopolamine was used to induce
transient cognitive impairment in monkeys trained in a delayed matching to sample task. The …

The muscarinic antagonist, quinuclidinyl benzilate (QNB), labeled with carbon 11 was used
as a radioligand to visualize in vivo by positron emission tomography (PET) the central …

To investigate changes in the somatostatinergic neurons of patients with Alzheimer's
disease (AD), we determined the somatostatin-like immunoreactivity (SLI) in post-mortem …

Memory deficits associated with aging and Alzheimer's disease have been linked to
cholinergic dysfunction. The present study investigated this hypothesis by comparing the …

Alzheimer's disease, the most common cause of senile dementia, is characterized by
intracellular formation of neurofibrillary tangles, extracellular deposits of beta amyloid as …

The present study evaluated effects of chronic treatment with tacrine and (−)-nicotine for 21
days on nicotinic and muscarinic acetylcholine receptors in the brains of old rats (24–25 …

It has been suggest that drugs specifically targeting muscarinic receptors will be useful in
treating Alzheimer's disease. We decided to determine if the response to such drugs may be …

We determined the concentration of the messenger RNA species which encode four (m1–
m4) of the five cloned muscarinic receptors in brains of Alzheimer's disease patients as …

The effects of low-dose chronic scopolamine on measures of cerebral perfusion and
muscarinic receptors were tested in eight Alzheimer's disease (AD) subjects and eight …

Choline acetyltransferase (ChAT) activity, the sedimentation and solubility forms of
acetylcholinesterase (AChE) as well as total (3H-quinuclidinyl benzilate, QNB) and M1 (3H …